Danish Software Stock News

Why Demant Is Back on Value Investors’ Radar Demant (CPSE:DEMANT) has drawn fresh attention after a recent analysis placed it among the most undervalued European stocks, pointing to a sizeable discount to estimated fair value based on discounted cash flows. See our latest analysis for Demant. At a share price of DKK209.0, Demant has seen a 6.85% 1 month share price return. However, the 1 year total shareholder return of 15.79% and 5 year total shareholder return of 35.49% indicate longer term...

The quarterly results for Danske Bank A/S ( CPH:DANSKE ) were released last week, making it a good time to revisit its...

DSV A/S ( CPH:DSV ) shareholders are probably feeling a little disappointed, since its shares fell 6.4% to kr.1,571 in...

Recent geopolitical tensions that earlier led to the closure of the Strait of Hormuz and instability in the Red Sea have forced container carriers such as A.P. Møller - Mærsk to reroute traffic, turning Africa and ports like Saudi Arabia’s Jeddah into new hubs amid longer transit times and congestion. This reshaping of trade lanes underlines how regional ports such as Sohar, Khorfakkan, Fujairah and Jeddah can quickly gain influence when core shipping corridors are disrupted. We’ll now...

As of late April 2026, European markets have been navigating a challenging landscape marked by geopolitical tensions and fluctuating economic indicators. Despite these hurdles, opportunities abound for investors willing to explore beyond the mainstream indices. Penny stocks, though often considered niche investments, can offer intriguing growth potential when they are backed by sound financial fundamentals. In this article, we will examine three European penny stocks that stand out for their...

DSV (CPSE:DSV) opened 2026 with Q1 results anchored by prior quarter revenue of about DKK71.7b and basic EPS of DKK4.72, set against trailing 12 month revenue of roughly DKK247.3b and EPS of DKK35.57. Over recent quarters, revenue has moved from about DKK43.5b in Q4 2024 to the DKK71.7b level in Q4 2025, while quarterly EPS shifted from DKK9.46 to DKK4.72, leaving investors focused on how much of the top line is converting into sustainable margins. See our full analysis for DSV. With the...

Wondering if Rockwool at a last close of DKK 185.8 is starting to look attractive, or if the price still does not quite line up with the underlying business. The stock has been choppy, with a 4.7% decline over the last 7 days, a 6.3% gain over 30 days, and longer-term returns of a 17.2% decline year to date and a 35.4% decline over 1 year, while the 3-year return sits at 19.9% and the 5-year return at a 24.0% decline. Recent coverage around Rockwool has focused on how the share price path...

Why Carlsberg’s expanded PepsiCo partnership matters for shareholders Carlsberg (CPSE:CARL B) has agreed to expand its long running collaboration with PepsiCo, taking over bottling in Denmark, Finland and the Baltic states from 2029 as existing Coca-Cola arrangements conclude. For you as an investor, this shift means Carlsberg is set to handle production, sales and distribution of PepsiCo drinks across all Nordic markets, plus Latvia, Estonia and Lithuania. That extends an arrangement that...

H. Lundbeck (CPSE:HLUN B) shares are in focus after the company reported new 6 month real world INFUSE study results for migraine drug eptinezumab at the American Academy of Neurology 2026 meeting. See our latest analysis for H. Lundbeck. The eptinezumab data arrives at a time when H. Lundbeck’s short term momentum is positive, with a 14.59% 1 month share price return and a 54.44% 1 year total shareholder return. However, the 90 day share price return of 2.16% decline suggests some earlier...

Coloplast recently revised its FY 2025/26 guidance, trimming expected organic growth to 5–6% and EBIT growth to around 5%, while recording a DKK 3.00 billion goodwill impairment on Kerecis following sales disruption from a Medicare reimbursement change and softer skin substitutes demand. This combination of lower growth expectations and a large impairment charge highlights how reimbursement shifts in a single niche can materially affect Coloplast’s broader outlook and capital allocation...

Royal Unibrew A/S has reported its Q1 2026 results, with sales rising to DKK 3,311 million and net income increasing to DKK 171 million, alongside basic and diluted earnings per share from continuing operations of DKK 3.5, all up from the same period last year. The company’s 25% EBIT increase, driven by margin expansion and market share gains while reaffirming its full-year 2026 outlook and running a share buyback program through August 14, 2026, highlights a focus on profitability and...

We'd be surprised if SKAKO A/S ( CPH:SKAKO ) shareholders haven't noticed that the MD, CEO & Non-Independent Director...

Genmab (CPSE:GMAB) has reported new clinical data for its antibody drug conjugate rinatabart sesutecan, known as Rina S, in advanced ovarian cancer. The therapy, in combination with bevacizumab, showed a tolerable safety profile with no new or unexpected safety signals in patients. The results were presented at a major oncology conference, adding fresh information on Genmab’s oncology pipeline. For investors tracking Genmab, the update on Rina S comes with the share price at DKK1,804.0 and...

Swiss Properties Invest A/S' ( CPH:SWISS ) stock wasn't much affected by its recent lackluster earnings numbers. We did...

TORM plc ( CPH:TRMD A ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.

Readers hoping to buy Scandinavian Tobacco Group A/S ( CPH:STG ) for its dividend will need to make their move shortly...

As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending the week up 3.92% in local currency terms. This positive sentiment is supported by hopes for a shorter-lived conflict and is reflected in gains across major stock indexes like Germany's DAX and Italy's FTSE MIB. In this environment, identifying promising stocks involves looking for companies with strong fundamentals that can...

In late March 2026, Vestas Wind Systems announced a series of new wind turbine orders across Germany, France, the UK and the USA, alongside long-term service agreements and deliveries stretching from 2026 to 2028, and separately revealed plans for a more than €250 million nacelle and hub factory in Scotland targeting its V236-15.0 MW offshore turbines. Taken together, the fresh onshore order intake and the conditional Scottish offshore factory plan underline how Vestas is tying near-term...

Wondering whether Ørsted at DKK158.45 is starting to look like value, or still priced for high expectations? This article breaks down what the current share price may be implying. The stock has returned 9.2% over the last 7 days and 5.1% over the past month, yet over 1 year it is down 7.6% and over 5 years it is down 71.1%. This raises questions about how investors are reassessing both risk and potential. Recent attention on Ørsted has focused on its position in renewable energy and how...

Investors may be wondering whether Bavarian Nordic is attractively priced at its current level, or if the recent run has already incorporated most of the value. The stock last closed at kr197.25, with returns of 3.8% over 7 days, 2.4% over 30 days, 2.3% year to date, 30.7% over 1 year, 1.0% over 3 years, and a 31.8% decline over 5 years. Recent news coverage has focused on Bavarian Nordic's role in vaccines and biopharmaceuticals. This has kept attention on the company as investors reassess...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...